GleamWall
中文EN

BUDZ WEED, INC.

Services-Commercial Physical & Biological Research · OTC · SEC CIK 1393772 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-49.2%
TTM EPS YoY-33.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-216.0%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets301.6%
Debt / equity—
Current ratio0.01x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.21x
Accruals ratio-170.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$0$0
Cost of revenue$0$0
Gross profit$0$0
SG&A expense$1.13M$351,116
Operating income-$1.33M-$529,992
Interest expense—$5,070
Pretax income-$1.37M-$510,317
Income tax$33$399
Net income-$1.37M-$510,716
EBITDA-$1.31M-$507,406
EPS (basic)—-0.00
EPS (diluted)-0.01-0.00
Weighted avg. shares (diluted)135.92M124.13M
Balance sheet
Cash & equivalents$33,130$159,355
Current assets$47,705$189,891
PP&E, net$476,467$496,354
Intangibles$30,983$33,583
Total assets$559,906$738,366
Current liabilities$1.25M$959,372
Total liabilities$1.25M$959,372
Shareholders' equity-$688,361-$221,006
Shares outstanding148.53M125.43M
Cash flow statement
Operating cash flow-$195,136-$415,524
Financing cash flow$70,103$285,269
Depreciation & amortization$22,487$22,586
Stock-based compensation$800,000$20,000

Free plan shows the latest 2 periods; Pro shows all 11 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.